News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

February 23, 2024

HLTH Inc. and GE Healthcare Reveal Healthcare-Themed Art Gallery

Author(s):

Mike Hollan

The gallery will be a part of the HLTH Europe event and will be open to all attendees.

Doug Healy

No More Barriers
Doug Healy

Healthcare brings out the artist in pharma.

HLTH Inc. announced its own art gallery, sponsored by GE HealthCare. In a press release, HLTH Inc. revealed that the gallery will be part of its inaugural HLTH Europe event, which will occur from June 17-20, 2024 in Amsterdam. The gallery will be open throughout the entire event and will be available to all attendees.

In a press release, HLTH Europe’s managing director Katy Fryatt said, “We are thrilled to launch the HLTH Europe Art Gallery with the support of the GE HealthCare team. Art is a powerful medium through which we can share our experiences and connect with each other. We encourage submissions from all stakeholders in the healthcare ecosystem from patient groups to care givers, clinicians and system leaders. The gallery will foster a sense of community among the whole healthcare ecosystem through art. Ultimately, we hope the gallery offers a reminder about why we are coming together at HLTH–for the benefit of patients."

HLTH is accepting submissions for the gallery from HCPs, patients, and caregivers. The gallery will include a variety of mediums, including paintings, digital art, and photography. Attendees of the gallery will also have access to interactive workshops on various visual art methods.

Simon Philip Rost, Chief Marketing Officer Enterprise Imaging, GE HealthCare, says, "We are proud to be part of this initiative at HLTH Europe. We recognise the therapeutic power of art and its contribution to patients' holistic wellbeing and would encourage everyone in the healthcare ecosystem to consider submitting their work. We look forward to providing a creative outlet for patients and healthcare professionals alike later this year in Amsterdam."

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.